AvalehtRARE • BMV
add
Ultragenyx Pharmaceutical Inc
Viimane sulgemishind
751,98 $
Aasta vahemik
594,48 $ - 751,98 $
Turuväärtus
3,95 mld USD
P/E suhe
-
Dividendimäär
-
Põhibörs
NASDAQ
Börsiuudised
.DJI
0,13%
Finantsandmed
Kasumiaruanne
Käive
Puhastulu
(USD) | märts 2024info | Y/Y muutus |
---|---|---|
Käive | 108,83 mln | 8,30% |
Põhitegevusega seonduv kulu | 78,16 mln | 1,98% |
Puhastulu | −170,68 mln | −4,09% |
Puhaskasumimarginaal | −156,83 | 3,88% |
Puhaskasum aktsia kohta | −2,03 | 12,70% |
EBITDA | −156,50 mln | −5,13% |
Tõhus maksumäär | −0,27% | — |
Bilansiaruanne
Kogu vara
Kõik kohustused
(USD) | märts 2024info | Y/Y muutus |
---|---|---|
Sularaha ja lühiajalised investeeringud | 412,08 mln | −34,52% |
Kogu vara | 1,31 mld | −5,52% |
Kõik kohustused | 1,17 mld | 0,33% |
Kogu omakapital | 140,26 mln | — |
Emiteeritud aktsiate arv | 83,07 mln | — |
Hinna ja väärtuse suhe P/B | 444,96 | — |
Varade tasuvus | −29,55% | — |
Kapitali tasuvus | −36,22% | — |
Rahavoog
Raha ja raha ekvivalentide muutus
(USD) | märts 2024info | Y/Y muutus |
---|---|---|
Puhastulu | −170,68 mln | −4,09% |
Põhitegevuse rahakäive | −190,73 mln | −21,59% |
Investeeringute raha | 94,44 mln | −15,16% |
Finantseerimise raha | −58,00 tuh | 91,97% |
Raha ja raha ekvivalentide muutus | −97,03 mln | −110,59% |
Tasuta rahavoog | −158,09 mln | −12,26% |
Teave
Ultragenyx is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami.
Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA. The company also has therapies approved outside the U.S. in Canada, Latin America, Europe, and Japan. Wikipedia
Tegevjuht
Asutatud
2010
Veebisait
Töötajate arv
1 276